Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia.

@article{Yamamoto2007IntravitrealB,
  title={Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia.},
  author={Izumi Yamamoto and Adam H Rogers and Elias Reichel and Paul A. Yates and Jay S. Duker},
  journal={The British journal of ophthalmology},
  year={2007},
  volume={91 2},
  pages={157-60}
}
OBJECTIVE To evaluate the safety and efficacy of intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation (CNV) due to pathological myopia. METHODS Consecutive series of primary or recurrent subfoveal CNV secondary to myopia treated with intravitreal bevacizumab 1.25 mg between August 2005 and January 2006 at the New England Eye Center, Boston, Massachusetts, USA, were reviewed retrospectively. Data from clinical examination, fundus photography, fluorescein… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 83 extracted citations

Choroidal neovascularization after intraocular foreign body injury.

Retinal cases & brief reports • 2012
View 3 Excerpts
Highly Influenced

Drug Delivery for the Retina and Posterior Segment Disease

Rakesh Kanwar, Yashwant V. Pathak
Springer International Publishing • 2018

Similar Papers

Loading similar papers…